{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:23:16Z","timestamp":1761895396687},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A major breakthrough in the treatment of acute lymphoblastic leukemia (ALL) was the availability of targeted therapies targeting either specific transcripts, such as bcr-abl fusion protein by tyrosine kinase inhibitors (TKIs), or specific antigens by mAbs. ALL blast cells express a variety of specific antigens (eg, CD19, CD20, CD22, CD33, and CD52) that serve as targets for mAbs. To date, the most data are available for anti-CD20 (rituximab), which has been combined with chemotherapy for the treatment of mature B-ALL\/Burkitt lymphoma. Studies with rituximab have also been completed in B-precursor ALL. Another antigen, CD19, is of great interest due to a very high rate of expression in ALL. It can be targeted by a bispecific mAb, blinatumomab, directed against CD19 and CD3. Smaller studies or case reports are also available for the anti-CD52 (alemtuzumab), anti-CD22 (epratuzumab), and anti-CD33 (gemtuzumab) mAbs. Available data demonstrate that mAb therapy in ALL is a highly promising treatment approach. However, several details for an optimal treatment approach, such as the required level of antigen expression, timing, schedule, dosage, and stage of disease, still need to be defined.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.243","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"243-249","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia"],"prefix":"10.1182","volume":"2011","author":[{"given":"Dieter","family":"Hoelzer","sequence":"first","affiliation":[{"name":"Goethe University Hospital, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111716141011800_B1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-003-0752-8","article-title":"Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects","volume":"83","author":"G\u00f6kbuget","year":"2004","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111716141011800_B2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111716141011800_B3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111716141011800_B4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2019111716141011800_B5","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling","volume":"283","author":"Walshe","year":"2008","journal-title":"J Biol Chem"},{"key":"2019111716141011800_B6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"issue":"4","key":"2019111716141011800_B7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111716141011800_B8","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111716141011800_B9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"2019111716141011800_B10","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","author":"Jeha","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2019111716141011800_B11","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1182\/blood-2011-01-329573","article-title":"Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia","volume":"117","author":"Bachanova","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111716141011800_B12","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"2019111716141011800_B13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood.V116.21.2124.2124","article-title":"CD20 up-regulation in induction therapy for childhood B lymphoblastic leukemia [abstract]","volume":"116","author":"Watt","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111716141011800_B14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD- Study Group","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"2019111716141011800_B15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"key":"2019111716141011800_B16","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL) [abstract]","volume":"104","author":"Hoelzer","year":"2004","journal-title":"Blood"},{"key":"2019111716141011800_B17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood.V116.21.858.858","article-title":"Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia\/lymphoma: Cancer and Leukemia Group B (CALGB) Study 10002 [abstract]","volume":"116","author":"Rizzieri","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111716141011800_B18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"2019111716141011800_B19","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/blood.V114.22.1667.1667","article-title":"Rituximab added to CODOX-M\/IVAC has no clear benefit compared to CODOX-M\/IVAC alone in adult patients with Burkitt lymphoma [abstract]","volume":"114","author":"Barnes A","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111716141011800_B20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"2019111716141011800_B21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V110.11.518.518","article-title":"High survival rate in adult Burkitt's lymphoma\/leukemia and diffuse large B-cell lymphoma with mediastinal envolvement [abstract]","volume":"110","author":"Hoelzer","year":"2007","journal-title":"Blood"},{"key":"2019111716141011800_B22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood.V108.11.2736.2736","article-title":"Novel Treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showng excellent outcome [abstract]","volume":"108","author":"Dunleavy","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2019111716141011800_B23","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111716141011800_B24","first-page":"481","article-title":"Immunochemotherapy with rituximab in adult CD20 B-precusor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT [abstract]","volume":"94","author":"Hoelzer","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"2019111716141011800_B25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V64.1.38.bloodjournal64138","article-title":"Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults","volume":"64","author":"Hoelzer","year":"1984","journal-title":"Blood"},{"issue":"24","key":"2019111716141011800_B26","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111716141011800_B27","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/cncr.11219","article-title":"Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311","volume":"97","author":"Szatrowski","year":"2003","journal-title":"Cancer"},{"issue":"5891","key":"2019111716141011800_B28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"2019111716141011800_B29","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/blood.V112.11.1926.1926","article-title":"Treatment with anti-CD19 BiTE antibody blinatumomab (MT103 \/ MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL): first results of an ongoing phase II study [abstract]","volume":"112","author":"Topp","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2019111716141011800_B30","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111716141011800_B31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"key":"2019111716141011800_B32","first-page":"844","article-title":"Clinical activity of the anti-CD19 BiTE\u00ae blinatumomab in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia: interim results of a phase 2 study [abstract]","author":"Topp","year":"2011","journal-title":"Haematologica"},{"key":"2019111716141011800_B33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V114.22.838.838","article-title":"Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102) [abstract]","volume":"114","author":"Stock","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111716141011800_B34","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"},{"issue":"25","key":"2019111716141011800_B35","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1038\/sj.onc.1210370","article-title":"Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies","volume":"26","author":"Leonard","year":"2007","journal-title":"Oncogene"},{"issue":"22","key":"2019111716141011800_B36","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111716141011800_B37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/10428190701882161","article-title":"Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg","volume":"49","author":"Cheung","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111716141011800_B38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ajh.21548","article-title":"Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia","volume":"84","author":"Papayannidis","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111716141011800_B39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.leukres.2004.08.011","article-title":"New anti-T cell immunotoxins for the clinic","volume":"29","author":"Frankel","year":"2005","journal-title":"Leuk Res"},{"issue":"22","key":"2019111716141011800_B40","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111716141011800_B41","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies","volume":"28","author":"Cheson","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/243\/1494879\/bep00111000243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/243\/1494879\/bep00111000243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:24:06Z","timestamp":1713187446000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/243\/96429\/Novel-AntibodyBased-Therapies-For-Acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.243","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}